OmniAb Inc. (NASDAQ:OABI) — Market Cap & Net Worth
Market Cap & Net Worth: OmniAb Inc. (OABI)
OmniAb Inc. (NASDAQ:OABI) has a market capitalization of $254.80 Million ($254.80 Million) as of June 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #15653 globally and #3651 in its home market, demonstrating a -1.68% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying OmniAb Inc.'s stock price $2.34 by its total outstanding shares 143955400 (143.96 Million). Review OmniAb Inc. (OABI) total liabilities to assess the company's total debt and financial obligations.
OmniAb Inc. Market Cap History: 2021 to 2026
OmniAb Inc.'s market capitalization history from 2021 to 2026. Data shows change from $1.44 Billion to $336.86 Million (-26.12% CAGR).
Index Memberships
OmniAb Inc. is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.01% | #425 of 976 |
|
NASDAQ Composite
IXIC
|
$41.03 Trillion | 0.00% | #1520 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.69 Trillion | 0.02% | #217 of 263 |
Weight: OmniAb Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
OmniAb Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how OmniAb Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
19.31x
OmniAb Inc.'s market cap is 19.31 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.44 Billion | $34.75 Million | -$27.04 Million | 41.43x | N/A |
| 2022 | $518.24 Million | $59.08 Million | -$22.33 Million | 8.77x | N/A |
| 2023 | $888.20 Million | $34.16 Million | -$50.62 Million | 26.00x | N/A |
| 2024 | $509.60 Million | $26.39 Million | -$62.03 Million | 19.31x | N/A |
Competitor Companies of OABI by Market Capitalization
Companies near OmniAb Inc. in the global market cap rankings as of June 19, 2026.
Key companies related to OmniAb Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
OmniAb Inc. Historical Marketcap From 2021 to 2026
Between 2021 and today, OmniAb Inc.'s market cap moved from $1.44 Billion to $ 336.86 Million, with a yearly change of -26.12%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $336.86 Million | +26.49% |
| 2025 | $266.32 Million | -47.74% |
| 2024 | $509.60 Million | -42.63% |
| 2023 | $888.20 Million | +71.39% |
| 2022 | $518.24 Million | -64.00% |
| 2021 | $1.44 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of OmniAb Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $254.80 Million USD |
| MoneyControl | $254.80 Million USD |
| MarketWatch | $254.80 Million USD |
| marketcap.company | $254.80 Million USD |
| Reuters | $254.80 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About OmniAb Inc.
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partne… Read more